Improving HPV Immunization Coverage
The National Improvement Partnership Network (NIPN) and the Academic Pediatric Association (APA) are collaborating on a national practice-based QI initiative, funded by CDC to improve adolescent HPV immunization rates, see attached project summary. This is a wonderful opportunity for practices to collaborate in your state and from around the country to strengthen office systems for delivery of the HPV vaccine and improve provider recommendations. Enrollment is due by December 15, 2017. For more information, contact Rachel Wallace-Brodeur at Rachel.Wallace-Brodeur@med.uvm.edu.
Delaware’s HPV Vaccination Quarterly Report
This quarter’s report includes 2016 NIS -Teen coverage estimates for adolescents aged 13-17 years for Delaware, in addition to distribution data for all CDC and non-CDC distributed Gardasil 9 vaccines. In order to review coverage estimates for all states and selected local areas, please review the recently released MMWR entitled “National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2016”, at https://www.cdc.gov/mmwr/volumes/66/wr/mm6633a2.htm.
- HPV vaccine prevents infection with HPV types associated with many cancers (cervical, vaginal & vulvar, anal, throat, penile) and genital warts.
- Approved for ages 9-26, males & females.
- Should be given as a 2 dose series, with the doses separated by 6-12 months.
- If series is started at age 15 or later, give a 3 dose series (2nd dose 1-2 months after 1st, 3rd 6 months after 1st)
For Your Patients:
CDC: HPV Vaccine for Preteens and Teens: English | Spanish
HPV Fact Sheet: English | Spanish
HPV Gardasil-9 Vaccine Information Statement (12/02/2016): English | Spanish
Steps for Increasing HPV Vaccination in Practice: English
National HPV Round Table Clearinghouse: RTC
HPV VACs Newsletter: September-October 2017 Partner Newsletter
HPV VACs (3/09/2016): Just the Facts
return to top
From the CDC’s Pinkbook:
Anogenital HPV infection is believed to be the most common sexually transmitted infection in the United States. An estimated 79 million persons are infected, and an estimated 14 million new HPV infections occur annually with half of these in persons 15-24 years.
Infection with low-risk, or nononcogenic types of HPV, such as types 6 and 11, can cause benign or low-grade cervical cell abnormalities, genital warts and laryngeal papillomas.
High-risk HPV types are detected in 99% of cervical cancers. Type 16 is the cause of approximately 50% of cervical cancers worldwide, and types 16 and 18 together account for about 70% of cervical cancers. Infection with a high-risk HPV type is considered necessary for the development of cervical cancer, but by itself it is not sufficient to cause cancer because the vast majority of women with HPV infection do not develop cancer.
In addition to cervical cancer, HPV infection is also associated with anogenital cancers less common than cervical cancer, such as cancer of the vulva, vagina, penis and anus. The association of genital types of HPV with non-genital cancers is less well established, but studies support a role for these HPV types in some oropharyngeal cancers.
return to top
HPV Vaccination Strategies for Cancer Prevention – October 2017
HPV VACs Partner Newsletter – April 2017
HPV Vaccination Report: Delaware, March 2017
MMWR: Use of a 2-Dose Schedule for HPV Vaccination – Updated Recommendations of the ACIP, December 2016
You Call The Shots, Module 8: HPV, updated February 2017
You are the key to HPV Cancer Prevention, updated April 2016
Talking to Parents about HPV Vaccine
return to top